All In Biotech

Drug Trial Radar · NCT06344533

Study of JMKX003142 Injection in Chinese Healthy Subjects

Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of JMKX003142 Injection Administered Randomly, Double-blind, Placebo-controlled, Single-ascending Dose and Multiple-ascending Doses in Chinese Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Apr 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

78

Planned (sponsor's estimate)

Start

Apr 10, 2024

Primary completion

Jan 31, 2025

Study completion May 30, 2025

Sponsor

Lead sponsor
JemincareIndustry
Sponsor type
Industry
Collaborators
Zhejiang Hangyu Pharmaceutical Co., Ltd.
First posted
Apr 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of JMKX003142 Injection Administered Randomly, Double-blind, Placebo-controlled, Single-ascending Dose and Multiple-ascending Doses in Chinese Healthy Adult Subjects

Conditions

  • Healthy Adult

Interventions

  • JMKX003142 InjectionDrug

    JMKX003142 Injection will be administered intravenously once in SAD cohorts and once daily in MAD cohorts for 5 consecutive days.

  • PlaceboDrug

    Matching placebo will be administered intravenously once in SAD cohorts and once daily in MAD cohorts for 5 consecutive days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of the Adverse Events that are related to the single dose treatmentTime frame: From Baseline to Day7
  2. Number of the Adverse Events that are related to the multiple dose treatmentTime frame: From Baseline to Day12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.